Better diagnosis, treatment, and drug-resistance detection for HIV-2
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
This project is making simple, affordable tests and treatment tools to find and treat drug-resistant HIV-2 in people living with HIV, especially in West and Central Africa.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11375294 on NIH RePORTER |
What this research studies
You would be offered faster, low-cost point-of-care viral load tests and quicker drug-resistance testing so clinicians can know sooner if HIV-2 is not responding to treatment. The team is adapting and validating laboratory assays and portable devices, and studying how the common single-tablet TLD regimen performs for people with HIV-2 or dual HIV-1/HIV-2. Researchers will use patient blood samples and clinical data from clinics to compare the new tests to standard lab methods and to monitor emergence of resistance. Pilot work will include training clinic staff and testing these tools in real-world care settings.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV-2 or dual HIV-1/HIV-2 infection, particularly those starting or showing signs of failure on first-line TLD therapy in West or Central Africa.
Not a fit: People with only HIV-1, those living outside the study regions, or those not seen at participating clinics are unlikely to directly benefit from this project.
Why it matters
Potential benefit: If successful, patients could get faster, cheaper viral-load and resistance results that lead to better treatment choices and fewer treatment failures.
How similar studies have performed: Point-of-care viral-load and resistance approaches have improved HIV-1 care in many settings, but applying these tools specifically to HIV-2 and dual infections is relatively new and less tested.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Gottlieb, Geoffrey Scott — University of Washington
- Study coordinator: Gottlieb, Geoffrey Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.